pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$BIIBBIOGEN INC.

$BIIB214.35-3.25%
Cambridge, MA, USupdated 58m ago

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia ; tofersen (Qalsody) for the treatment of ALS; and dimethyl fum

read more…

SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
13
marketed
5
phase 3
3
catalysts ytd
6
approvals ytd
1
recalls ytd
0

Pipeline(13)

view full pipeline →
pipeline depth13 products
Phase 1: 2Phase 2: 1Phase 3: 3Marketed: 5Discontinued: 1Unknown: 1
2Phase 11Phase 23Phase 35Marketed1Discontinued1Unknown
Marketed
diroximel fumarate DR
Relapsing Remitting Multiple Sclerosis (RRMS)
Marketed
natalizumab
Crohn's Disease (Regional Enteritis)
Marketed
nusinersen
Spinal Muscular Atrophy (SMA)
Marketed
peginterferon beta-1a
Progressive Relapsing Multiple Sclerosis (PRMS)
Marketed
tofersen sodium
Amyotrophic Lateral Sclerosis
Phase 3
felzartamab
Membranous Glomerulonephritis
Phase 3
litifilimab
Cutaneous Lupus Erythematosus
C-type lectin domain family 4 member C
Phase 3
salanersen
Spinal Muscular Atrophy (SMA)
Phase 2
diranersen
Alzheimer's Disease
Phase 1
BIIB-142
Lupus Nephritis
Phase 1
izastobart
Solid Tumor
Discontinued
Aduhelm
Alzheimer's disease (withdrawn from market 2024)

📅 Upcoming

Oct 29, 2026
earnings
$BIIB214.35-3.25%
in 2mo
BIOGEN INC. earnings
BIOGEN INC.
→

🕒 Recent(90d)

earnings (2)
Jul 30, 2026
earnings
$BIIB214.35-3.25%
21d ago
BIOGEN INC. earnings
BIOGEN INC.
→
Jul 29, 2026
earnings
$BIIB214.35-3.25%
22d ago
BIOGEN INC. earnings
BIOGEN INC.
→
view all catalysts →

Insider activity

source: SEC Form 4
routine RSU / option mechanics (3)
  • Apr 1, 26tax coverGodbout Sean · Chief Accounting Officer54 sh
  • Apr 1, 26option exerciseGodbout Sean · Chief Accounting Officer181 sh
  • Apr 1, 26option exerciseGodbout Sean · Chief Accounting Officer181 sh
🐶 Hiring Signal
next earnings Oct 29, 2026
209 open roles at BIOGEN INC. →

Where BIOGEN INC. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaCNS / Neuroscience 30Immunology & Inflammation 12Rare Disease 8Nephrology 7Hematology 2Oncology 1
departmentCommercial 35Manufacturing / CMC 25Medical Affairs 15Business Development & Sales 15Market Access 13Regulatory 13

News

no news has mentioned this company yet
identifiers
ticker
$BIIB
SEC CIK
0000875045
country
US
source
sec_tickers
top tags
Immunology3ALS1Alzheimer's Disease1Lupus1Oncology1
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 11m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?